@

PEPperPRINT and Sciomics announce Partnership Agreement

 

Heidelberg, 18th November, 2014

 

Sciomics and PEPperPRINT agreed on a partnership for the co-distribution and co-marketing of their product and service portfolios with the aim to provide a comprehensive microarray toolbox for antibody characterization and biomarker discovery.

 

A joint two-step process for antibody characterization will enable the selection of the optimal antibody from a set of antibody candidates for therapeutic, diagnostic or research purposes. Sciomics will offer its custom antibody microarray platform as well as protein arrays for target binding validation and cross-reactivity analysis. Selected candidates will be further characterized by epitope mapping and epitope substitution scans provided by PEPperPRINT to identify conserved and variable amino acids as well as possible cross-reactions from a bioinformatics analysis of conserved core motifs.

 

The combination of peptide and antibody microarrays by PEPperPRINT and Sciomics further provides a powerful approach for discovery, in-depth characterization and validation of new serum biomarkers including antibodies and serum proteins. A combination of the core strengths of the respective platforms enables a robust and cost-efficient discovery of protein as well as autoantibody biomarker candidates in a highly multiplexed fashion. This increases the likelihood of identifying the optimal biomarker candidates and furthermore can increase the assay accuracy by combining information derived from both platforms.

 

The partnership agreement is based on a long lasting research relationship and highest appreciation of Sciomics scientific competences. A combination of the core technologies of both companies allows customers to benefit from our complementary and powerful microarray tool box” says Dr. Volker Stadler, CEO of PEPperPRINT. “The fact that both companies are located in Heidelberg certainly facilitates logistics and scientific collaboration and underlines the strength of the Heidelberg biotech cluster.”

 

"Sciomics is very glad to have entered into a partnership with PEPperPRINT. This complements our own expertise and portfolio in antibody characterization with the strong expertise of the PEPperPRINT team." says Dr. Christoph Schröder, CEO of Sciomics. "For biomarker research, combining the powerful microarray platforms of PEPperPRINT and Sciomics enables a most comprehensive coverage of all topics concerning discovery, verification as well as in-depth characterization of biomarker candidates. This partnership enables us to provide the maximum amount of value to our customer's projects."

 

Click here for Press Release as pdf-file.

 

 

 

 

PEPperPRINT
Dr. Lisa Steinbrück
Head of Business Development
Rischerstr. 12
D-69123 Heidelberg
Germany

Phone: +49 (0)6221 72644-89
Fax : +49 (0)6221 72644-75
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: www.pepperprint.com

Sciomics GmbH
Dr. Ronny Schmidt
Business Development
Schneidmühlstr. 19
D-69115 Heidelberg
Germany

Phone:
+49 (0) 6221 3283140
Fax :
+49 (0) 6221 4294834
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: http://www.sciomics.de

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

Our scioPhospho analysis combines protein expression profiling using scioDiscover with analysis of the corresponding protein's phosphorylation status. More than 1,400 proteins are analyzed in parallel, covering key pathways in diseases such as cancer, neurological disorders and organ failure.  This combination provides a comprehensive overview of signaling events and pathway activity…
Read more
scioUbi: protein profiling and ubiquitination status

scioUbi: protein profiling and ubiquitination status

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse more than 1,400 proteins in a single assay.   Features Screen…
scioDiscover - Protein Profiling on the Expression Level

scioDiscover - Protein Profiling on the Expression Level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell Surface Marker and Cytokine Profiling

scioCD - Cell Surface Marker and Cytokine Profiling

Characterize Your Cell Type! Cell Composition Analysis in Tissue Samples CD-Marker Expression Profiles Increased Throughput at High Sensitivity Levels High Reproducibility       Our scioCD profiling service covers 349 different…
scioCyto : Cytokine Profiling

scioCyto : Cytokine Profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell…

COVID-19 related activities and services

covid 19 portfolio web

News

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | New Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023)
New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)
New Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)
New Sciomics Proteomics Research Blog has Launched!

Sciomics Protomics Research Blog

 

At Sciomics, we are dedicated to advancing healthcare through proteomics research. We are collaborating with research groups and big pharma, alongside our in-house biomarker research initiatives. To make this research more accessible to you, we are launching the new Sciomics science blog!

The first study we will feature was published this year in a journal in the Nature publishing group. It's a topic that affects us all. Any guesses? Stay tuned!

 

 

Testimonials

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD